Status:
COMPLETED
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study will evaluate the safety and efficacy of MabThera in patients with active rheumatoid arthritis who have had an inadequate response or were intolerant to treatment with methotrexate. Eligibl...
Eligibility Criteria
Inclusion
- adult patients, \>=18 years of age;
- receiving out-patient treatment;
- experienced an inadequate response to previous or current treatment with methotrexate.
Exclusion
- rheumatic autoimmune disease other than RA, or significant systemic involvement secondary to RA;
- history of, or current, inflammatory joint disease other than RA;
- previous treatment with any cell-depleting therapies.
Key Trial Info
Start Date :
October 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT00934648
Start Date
October 1 2007
End Date
November 1 2010
Last Update
June 10 2014
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Casablanca, Morocco, 20000
2
Casablanca, Morocco, 20100
3
Marrakesh, Morocco, 40000
4
Rabat, Morocco, 10150